A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial

Autor: William A Gray, Koen Keirse, Yoshimitsu Soga, Andrew Benko, Anvar Babaev, Yoshiaki Yokoi, Henrik Schroeder, Jeffery T Prem, Andrew Holden, Jeffrey Popma, Michael R Jaff, Juan Diaz-Cartelle, Stefan Müller-Hülsbeck, Thomas Albrecht, Kenji Ando, Michael J Bacharach, William Bachinsky, Danielle Bajakian, Robert Beasley, James Benenati, Mark Burket, Joseph Cardenas, Tony Das, Randall De Martino, Hannes Deutschmann, Daniel Dulas, Robert Feldman, Mark Fugate, Lawrence Garcia, Jaafer Golzar, Rao Gutta, Patrick Hall, Stewart Hawkins, Steve Henao, Benjamin Herdrich, Keisuke Hirano, Safwan Jaalouk, Sean Janzer, Daizo Kawasaki, Yazan Khatib, Kimihiko Kichikawa, Ethan Korngold, Christian Loewe, Louis Lopez, Henry Lui, Toshiaki Mano, Robert Mendes, Akira Miyamoto, Masato Nakamura, David O'Connor, Takao Ohki, James Park, Richard Powell, Antonis Pratsos, Jeffery Prem, Vikram Rao, John Rashid, Robert Rhee, Jason Ricci, Dierk Scheinert, Herman Schroë, Peter O Simon, Gagan Singh, Kongteng Tan, Paul Tolerico, Thodur Vasudevan, Frank Vermassen, Martin Werner, Bret Wiechmann, Hiroyoshi Yokoi, Thomas Zeller

Publikováno v: The Lancet. 392:1541-1551

Summary Background The clinical effect of a drug-eluting stent in the femoropopliteal segment has not been investigated in a randomised trial with a contemporary comparator. The IMPERIAL study sought to compare the safety and efficacy of the polymer-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40ed43af365d78057b97ec5f69148ab8
https://doi.org/10.1016/s0140-6736(18)32262-1